JP2006520781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006520781A5 JP2006520781A5 JP2006507006A JP2006507006A JP2006520781A5 JP 2006520781 A5 JP2006520781 A5 JP 2006520781A5 JP 2006507006 A JP2006507006 A JP 2006507006A JP 2006507006 A JP2006507006 A JP 2006507006A JP 2006520781 A5 JP2006520781 A5 JP 2006520781A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- cancer
- tumor
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 11
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 108020004459 Small interfering RNA Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 239000004055 small Interfering RNA Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000005907 cancer growth Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 210000004994 reproductive system Anatomy 0.000 claims 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45367203P | 2003-03-10 | 2003-03-10 | |
| PCT/US2004/007198 WO2004081190A2 (en) | 2003-03-10 | 2004-03-09 | Uses of il-23 agonists and antagonists; related reagents |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007046287A Division JP2007197453A (ja) | 2003-03-10 | 2007-02-26 | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
| JP2010200382A Division JP2011032275A (ja) | 2003-03-10 | 2010-09-07 | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006520781A JP2006520781A (ja) | 2006-09-14 |
| JP2006520781A5 true JP2006520781A5 (enExample) | 2007-04-12 |
| JP4605798B2 JP4605798B2 (ja) | 2011-01-05 |
Family
ID=32990805
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507006A Expired - Fee Related JP4605798B2 (ja) | 2003-03-10 | 2004-03-09 | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
| JP2007046287A Pending JP2007197453A (ja) | 2003-03-10 | 2007-02-26 | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
| JP2010200382A Withdrawn JP2011032275A (ja) | 2003-03-10 | 2010-09-07 | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
| JP2013168870A Pending JP2014005286A (ja) | 2003-03-10 | 2013-08-15 | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007046287A Pending JP2007197453A (ja) | 2003-03-10 | 2007-02-26 | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
| JP2010200382A Withdrawn JP2011032275A (ja) | 2003-03-10 | 2010-09-07 | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
| JP2013168870A Pending JP2014005286A (ja) | 2003-03-10 | 2013-08-15 | Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US7282204B2 (enExample) |
| EP (2) | EP2108658B1 (enExample) |
| JP (4) | JP4605798B2 (enExample) |
| CN (1) | CN1759123B (enExample) |
| AT (1) | ATE440864T1 (enExample) |
| AU (2) | AU2004219625B9 (enExample) |
| BR (1) | BRPI0408247A (enExample) |
| CA (1) | CA2518262C (enExample) |
| CL (1) | CL2004000467A1 (enExample) |
| CY (1) | CY1109468T1 (enExample) |
| DE (1) | DE602004022781D1 (enExample) |
| DK (1) | DK1601694T3 (enExample) |
| ES (1) | ES2330220T3 (enExample) |
| MX (1) | MXPA05009717A (enExample) |
| NO (1) | NO20054630L (enExample) |
| NZ (2) | NZ541898A (enExample) |
| PL (1) | PL1601694T3 (enExample) |
| PT (1) | PT1601694E (enExample) |
| SI (1) | SI1601694T1 (enExample) |
| TW (2) | TWI439285B (enExample) |
| WO (1) | WO2004081190A2 (enExample) |
| ZA (1) | ZA200506879B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2004042009A2 (en) | 2002-10-30 | 2004-05-21 | Genentech, Inc. | Inhibition of il-17 production |
| TWI439285B (zh) * | 2003-03-10 | 2014-06-01 | Merck Sharp & Dohme | Ｉｌ－２３激動劑及拮抗劑之用途及相關試劑 |
| AU2004239288B2 (en) * | 2003-05-09 | 2010-01-28 | Centocor, Inc. | IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
| JP4903061B2 (ja) * | 2004-02-17 | 2012-03-21 | シェーリング コーポレイション | Ｉｌ−２３活性を調節する方法；関連する試薬 |
| US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| RU2006135119A (ru) * | 2004-03-05 | 2008-04-10 | Аркемикс Корп. (Us) | Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний |
| AR051444A1 (es) * | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| WO2006068987A2 (en) * | 2004-12-20 | 2006-06-29 | Schering Corporation | Uses of il-23 antagonists in the treatment of diabetes mellitus |
| WO2007005647A2 (en) * | 2005-06-30 | 2007-01-11 | Archemix Corp. | Polynucleotides and polypeptides of the il-12 family of cytokines |
| AU2012258409B2 (en) * | 2005-06-30 | 2016-01-07 | Centocor, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
| PT1896073E (pt) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
| ES2347690T3 (es) * | 2005-08-25 | 2010-11-03 | Eli Lilly And Company | Anticuerpos anti-il-23. |
| ME02705B (me) * | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
| EP2116258A1 (en) | 2005-09-01 | 2009-11-11 | Schering Corporation | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease |
| PT2548577T (pt) * | 2005-12-29 | 2017-05-29 | Janssen Biotech Inc | Anticorpos humanos anti-il-23, composições, métodos e usos |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| EP1882699A1 (en) * | 2006-07-27 | 2008-01-30 | Heinfried Radeke | Regulation of interleukin-23 |
| TWI426918B (zh) * | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| SI2426144T1 (sl) | 2007-02-23 | 2019-02-28 | Merck Sharp & Dohme Corp. | Umetno proizvedena anti-IL23P19 antitelesa |
| CN101663320A (zh) | 2007-02-23 | 2010-03-03 | 先灵公司 | 工程改造的抗IL-23p19抗体 |
| US8119133B2 (en) | 2007-02-28 | 2012-02-21 | Schering Corporation | Engineered anti-IL-23R antibodies |
| CN101668531B (zh) | 2007-02-28 | 2014-05-07 | 默沙东公司 | 用于治疗免疫病症的联合治疗 |
| AU2008273814A1 (en) * | 2007-07-06 | 2009-01-15 | Valorisation Hsj, Societe En Commandite | IL-23 receptor antagonists and uses thereof |
| AR068723A1 (es) * | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| US20100331545A1 (en) | 2007-10-24 | 2010-12-30 | Nippon Chemiphar Co., Ltd. | Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
| NZ588674A (en) * | 2008-05-05 | 2013-02-22 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| WO2010027767A1 (en) * | 2008-08-27 | 2010-03-11 | Schering Corporation | Engineered anti-il-23r antibodies |
| US20110183859A1 (en) * | 2008-09-25 | 2011-07-28 | The United States Of America, As Represented By The Secretary, | Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis |
| ES2469802T3 (es) * | 2008-10-20 | 2014-06-20 | Valipharma | Métodos y usos que implican aberraciones genéticas de NAV 3 y expresión aberrante de múltiples genes |
| EP2414393A1 (en) * | 2009-04-01 | 2012-02-08 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| SG175276A1 (en) * | 2009-05-05 | 2011-11-28 | Novimmune Sa | Anti-il-17f antibodies and methods of use thereof |
| EP2456787A4 (en) * | 2009-07-24 | 2013-01-30 | Univ Leland Stanford Junior | CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE |
| US20110086806A1 (en) * | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Polypeptides that Bind IL-23R |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
| PE20141162A1 (es) | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| USRE49026E1 (en) | 2011-06-14 | 2022-04-12 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| KR102124758B1 (ko) | 2012-05-03 | 2020-06-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-ｉｌ-23ｐ19 항체 |
| WO2014004436A2 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| AR094877A1 (es) | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
| WO2016014775A1 (en) | 2014-07-24 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of il-23a related diseases |
| UA123624C2 (uk) | 2014-09-03 | 2021-05-05 | Бьорінґер Інґельхайм Інтернаціональ Ґмбх | Сполука, специфічна до іл-23а та фнп-альфа, та її застосування |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| SG11201705728RA (en) | 2015-02-04 | 2017-08-30 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| JP6871876B2 (ja) | 2015-03-11 | 2021-05-19 | ラッシュ ユニヴァーシティ メディカル センター | がんを治療するための組成物と方法 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| JP7516250B2 (ja) | 2018-03-05 | 2024-07-16 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| IL283192B2 (en) | 2018-11-20 | 2025-10-01 | Janssen Biotech Inc | A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody |
| MX2021014302A (es) | 2019-05-23 | 2022-01-04 | Janssen Biotech Inc | Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa. |
| US20230220031A1 (en) * | 2020-04-17 | 2023-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered il-12 and il-23 polypeptides and uses thereof |
| CN115768466A (zh) | 2020-05-21 | 2023-03-07 | 詹森生物科技公司 | 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6176962B1 (en) | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
| US5856457A (en) | 1991-03-29 | 1999-01-05 | Genentech, Inc. | Nucleic acids encoding a human IL-8 receptor |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US5888530A (en) | 1995-07-21 | 1999-03-30 | The General Hospital Corporation | Method of enhancing delivery of a pharmaceutical formulation |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6060284A (en) * | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| US5842787A (en) | 1997-10-09 | 1998-12-01 | Caliper Technologies Corporation | Microfluidic systems incorporating varied channel dimensions |
| US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
| WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| ES2300276T5 (es) * | 1999-09-09 | 2017-06-02 | Merck Sharp & Dohme Corp. | P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas |
| CA2408571C (en) * | 2000-05-10 | 2014-04-29 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| EP1326978A2 (en) * | 2000-10-06 | 2003-07-16 | Immunex CorporatioN | Hematopoietin receptors hpr1 and hpr2 |
| WO2002097048A2 (en) * | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| TWI439285B (zh) * | 2003-03-10 | 2014-06-01 | Merck Sharp & Dohme | Ｉｌ－２３激動劑及拮抗劑之用途及相關試劑 |
-
2004
- 2004-03-09 TW TW100126443A patent/TWI439285B/zh not_active IP Right Cessation
- 2004-03-09 AU AU2004219625A patent/AU2004219625B9/en not_active Ceased
- 2004-03-09 BR BRPI0408247-8A patent/BRPI0408247A/pt not_active IP Right Cessation
- 2004-03-09 DK DK04718824T patent/DK1601694T3/da active
- 2004-03-09 MX MXPA05009717A patent/MXPA05009717A/es active IP Right Grant
- 2004-03-09 NZ NZ541898A patent/NZ541898A/en not_active IP Right Cessation
- 2004-03-09 SI SI200431281T patent/SI1601694T1/sl unknown
- 2004-03-09 US US10/797,157 patent/US7282204B2/en not_active Expired - Lifetime
- 2004-03-09 CN CN2004800067148A patent/CN1759123B/zh not_active Expired - Fee Related
- 2004-03-09 CL CL200400467A patent/CL2004000467A1/es unknown
- 2004-03-09 DE DE602004022781T patent/DE602004022781D1/de not_active Expired - Lifetime
- 2004-03-09 EP EP09163834.6A patent/EP2108658B1/en not_active Expired - Lifetime
- 2004-03-09 JP JP2006507006A patent/JP4605798B2/ja not_active Expired - Fee Related
- 2004-03-09 PT PT04718824T patent/PT1601694E/pt unknown
- 2004-03-09 WO PCT/US2004/007198 patent/WO2004081190A2/en not_active Ceased
- 2004-03-09 ES ES04718824T patent/ES2330220T3/es not_active Expired - Lifetime
- 2004-03-09 CA CA2518262A patent/CA2518262C/en not_active Expired - Fee Related
- 2004-03-09 PL PL04718824T patent/PL1601694T3/pl unknown
- 2004-03-09 TW TW093106213A patent/TWI357336B/zh not_active IP Right Cessation
- 2004-03-09 AT AT04718824T patent/ATE440864T1/de active
- 2004-03-09 EP EP04718824A patent/EP1601694B1/en not_active Expired - Lifetime
- 2004-03-09 NZ NZ567860A patent/NZ567860A/en not_active IP Right Cessation
-
2005
- 2005-08-26 ZA ZA200506879A patent/ZA200506879B/en unknown
- 2005-10-07 NO NO20054630A patent/NO20054630L/no not_active Application Discontinuation
-
2007
- 2007-02-26 JP JP2007046287A patent/JP2007197453A/ja active Pending
- 2007-08-31 US US11/848,462 patent/US20080057058A1/en not_active Abandoned
-
2009
- 2009-08-24 US US12/546,230 patent/US8034341B2/en not_active Expired - Lifetime
- 2009-10-06 CY CY20091101030T patent/CY1109468T1/el unknown
-
2010
- 2010-08-16 AU AU2010212372A patent/AU2010212372B2/en not_active Ceased
- 2010-09-07 JP JP2010200382A patent/JP2011032275A/ja not_active Withdrawn
-
2011
- 2011-10-10 US US13/270,077 patent/US20120034219A1/en not_active Abandoned
-
2013
- 2013-08-15 JP JP2013168870A patent/JP2014005286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006520781A5 (enExample) | ||
| Takahashi et al. | The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer | |
| Tringler et al. | B7-h4 is highly expressed in ductal and lobular breast cancer | |
| Wu et al. | The non-coding RNA llme23 drives the malignant property of human melanoma cells | |
| JP2016533395A5 (enExample) | ||
| JP2005225884A5 (enExample) | ||
| JP2011157397A5 (enExample) | ||
| HRP20100412T1 (hr) | Identifikacija površinskih antigena radi dijagnoze i liječenja tumora | |
| KR20190021252A (ko) | c-MAF 상태에 기초한 유방암의 치료 | |
| JP2005535601A5 (ja) | 可溶型の炭酸脱水酵素IX(s-CA IX)、s-CA IXを検出するためのアッセイ、CA IXとHER-2/neu/c-erbB-2の同時発現、非免疫優性エピトープに対するCA IX特異的モノクローナル抗体 | |
| RU2013113439A (ru) | Идентификация опухолеассоциированных антигенов для диагностики и терапии | |
| CN103328500B (zh) | 用于癌症的诊断和治疗的方法和化合物 | |
| JP2007506417A5 (enExample) | ||
| Atula et al. | Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome | |
| JP2020510409A5 (enExample) | ||
| JP2018508532A5 (enExample) | ||
| JP2008508858A5 (enExample) | ||
| JP2008535856A5 (enExample) | ||
| JP2013543117A5 (enExample) | ||
| US20170173005A1 (en) | Method for detecting or treating triple negative breast cancer | |
| JP2005520543A5 (enExample) | ||
| JP2008535855A5 (enExample) | ||
| CN107090513A (zh) | Gm2a基因作为男性骨质疏松症诊断和预后的标志物 | |
| CN114182014A (zh) | 抑制结直肠癌增殖和转移的靶标及其应用 | |
| GB0616929D0 (en) | Antibodies, assays and hybridomas |